title: Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
authors.affiliation: Centre Eugène Marquis, CHU Pontchaillou, Rennes, France.
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: R
authors.initials: R
authors.lastname: Somers
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: D
authors.initials: D
authors.lastname: Crowther
authors.forename: T
authors.initials: T
authors.lastname: Tursz
authors.forename: A
authors.initials: A
authors.lastname: Santoro
authors.forename: W P
authors.initials: WP
authors.lastname: Steward
authors.forename: M A
authors.initials: MA
authors.lastname: Lentz
authors.forename: M
authors.initials: M
authors.lastname: van Glabbeke
authors.forename: H T
authors.initials: HT
authors.lastname: Mouridsen
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine